BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27735065)

  • 1. Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.
    Mackenzie IS; Morant SV; Wei L; Thompson AM; MacDonald TM
    Br J Clin Pharmacol; 2017 Mar; 83(3):653-663. PubMed ID: 27735065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study.
    Mackenzie IS; Macdonald TM; Thompson A; Morant S; Wei L
    BMJ; 2012 Jul; 345():e4447. PubMed ID: 22797844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study.
    Hiebert BM; Janzen BW; Sanjanwala RM; Ong AD; Feldman RD; Kim JO
    Br J Clin Pharmacol; 2021 Apr; 87(4):1801-1813. PubMed ID: 32986870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of spironolactone use with risk of urinary tract cancer in the general population: A matched population-based cohort study.
    Chen LC; Yang HJ; Yu BH; Lee MS; Lin HY; Chiou WY; Liu DW; Hsu FC; Chew CH; Hung SK
    PLoS One; 2024; 19(3):e0300391. PubMed ID: 38536840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases.
    Strongman H; Gadd S; Matthews A; Mansfield KE; Stanway S; Lyon AR; Dos-Santos-Silva I; Smeeth L; Bhaskaran K
    Lancet; 2019 Sep; 394(10203):1041-1054. PubMed ID: 31443926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spironolactone and gastrointestinal bleeding: a population based study.
    Russo A; Autelitano M; Bisanti L
    Pharmacoepidemiol Drug Saf; 2008 May; 17(5):495-500. PubMed ID: 18327868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients.
    Hicks BM; Murray LJ; Hughes C; Cardwell CR
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):830-40. PubMed ID: 26017274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.
    Kaye JA; Margulis AV; Fortuny J; McQuay LJ; Plana E; Bartsch JL; Bui CL; Perez-Gutthann S; Arana A
    Pharmacotherapy; 2017 Jun; 37(6):673-683. PubMed ID: 28370075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: database analyses from Germany and the UK.
    Kowall B; Stang A; Rathmann W; Kostev K
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):865-74. PubMed ID: 26132313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin use and risk of cancer in patients with type 2 diabetes: a cohort study of primary care records using inverse probability weighting of marginal structural models.
    Farmer RE; Ford D; Mathur R; Chaturvedi N; Kaplan R; Smeeth L; Bhaskaran K
    Int J Epidemiol; 2019 Apr; 48(2):527-537. PubMed ID: 30753459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database.
    Bhaskaran K; Douglas I; Evans S; van Staa T; Smeeth L
    BMJ; 2012 Apr; 344():e2697. PubMed ID: 22531797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial.
    Desai AS; Liu J; Pfeffer MA; Claggett B; Fleg J; Lewis EF; McKinlay S; O'Meara E; Shah SJ; Sweitzer NK; Solomon S; Pitt B
    J Card Fail; 2018 May; 24(5):313-320. PubMed ID: 29572190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of spironolactone on the risks of mortality and hospitalization for heart failure in pre-dialysis advanced chronic kidney disease: A nationwide population-based study.
    Tseng WC; Liu JS; Hung SC; Kuo KL; Chen YH; Tarng DC; Hsu CC
    Int J Cardiol; 2017 Jul; 238():72-78. PubMed ID: 28363684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort.
    Abbas S; Ihle P; Harder S; Schubert I
    Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):406-13. PubMed ID: 25683504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone use and the risk of breast and gynecologic cancers.
    Biggar RJ; Andersen EW; Wohlfahrt J; Melbye M
    Cancer Epidemiol; 2013 Dec; 37(6):870-5. PubMed ID: 24189467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa.
    Jung JM; Lee KH; Kim YJ; Chang SE; Lee MW; Choi JH; Won CH; Lee WJ
    JAMA Dermatol; 2020 Aug; 156(8):844-853. PubMed ID: 32459291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
    Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
    Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Pericarditis and Cancer Risk: A Matched Cohort Study Using Linked UK Primary and Secondary Care Data.
    Søgaard KK; Sørensen HT; Smeeth L; Bhaskaran K
    J Am Heart Assoc; 2018 Aug; 7(16):e009428. PubMed ID: 30369322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink.
    Matthews A; Langan SM; Douglas IJ; Smeeth L; Bhaskaran K
    PLoS Med; 2016 Jun; 13(6):e1002037. PubMed ID: 27299522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.